Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): positioning statement from the Spanish Association of Urology.
Villavicencio H, Hernández C, Gómez A, Cózar JM, Rodríguez-Antolín A, Prieto L, de Cabo M, Malet JM, Extramiana J, Mata J, Arrabal M, Server G, Solsona E, Del Valle JI, Miguélez E, Gutiérrez E, Elizalde A, Mateos J, Artiles JL, Jiménez-Cidre M, Nalda LM, Cruz N, Ozonas M, Caffaratti J, Esteban M, Unda M, Reina C, Alvarez-Ossorio JL, Lledó E, Angulo JC.
Villavicencio H, et al.
Actas Urol Esp. 2013 Jun;37(6):321-3. doi: 10.1016/j.acuro.2013.04.001. Epub 2013 May 23.
Actas Urol Esp. 2013.
PMID: 23706692
English, Spanish.
No abstract available.